keyword
https://read.qxmd.com/read/38635826/effects-of-cucurbita-moschata-squash-butternut-seed-paste-in-improving-zinc-and-iron-status-in-children-attending-early-childhood-development-centres-in-limpopo-province-south-africa
#1
JOURNAL ARTICLE
Selekane Ananias Motadi, Xikombiso Gertrude Mbhenyane, Mthokozisi Kwazi Zuma, Jeanne H Freeland Graves
Cucurbita moschata (Butternut squash) seeds are a rich source of nutrition containing nutrients including iron, zinc, copper, calcium, potassium, and phosphorus. The aim of this study was to determine if Cucurbita Moschata squash seed paste improves zinc and iron status, anthropometric status, and dietary intake in preschool children. A pretest-posttest control group trial using cluster randomisation was conducted over 6 months. Four preschools were randomly assigned to receive 100 g of intervention or 100 g of a placebo as the control to enhance iron and zinc status...
2024: PloS One
https://read.qxmd.com/read/38635812/exploring-acupuncture-as-a-treatment-for-insomnia-in-perimenopausal-women-with-stable-angina-pectoris-a-protocol-for-a-randomized-double-blind-placebo-controlled-clinical-trial
#2
JOURNAL ARTICLE
Rui Shi, Wenyi Meng, Zhaozheng Liu, Wen Xue, Xingyu Chen, Yue Deng
BACKGROUND: Insomnia has emerged as a major public health issue jeopardizing human wellbeing. Furthermore, insomnia and angina arise concomitantly and exert reciprocal effects. Multiple studies suggest that perimenopausal females are more prone to experiencing both angina and insomnia, consequently substantially compromising their quality of life.Credible evidence suggests that acupuncture exerts a beneficial impact in alleviating insomnia. Nevertheless, the exhaustive investigation into the potential of acupuncture for mitigating insomnia co-occurring with stable angina in perimenopausal females remains a realm yet to be traversed in the realm of randomized controlled trials...
2024: PloS One
https://read.qxmd.com/read/38635724/evaluating-the-efficacy-and-safety-of-mavacamten-in-hypertrophic-cardiomyopathy-a-systematic-review-and-meta-analysis-focusing-on-qualitative-assessment-biomarkers-and-cardiac-imaging
#3
JOURNAL ARTICLE
Rahul Vyas, Viraj Panchal, Shubhika Jain, Manush Sondhi, Mansunderbir Singh, Keerthish Jaisingh, Sahith Reddy Thotamgari, Anuj Thakre, Kalgi Modi
BACKGROUND: Hypertrophic Cardiomyopathy (HCM) is a complex cardiac condition characterized by hypercontractility of cardiac muscle leading to a dynamic obstruction of left ventricular outlet tract (LVOT). Mavacamten, a first-in-class cardiac myosin inhibitor, is increasingly being studied in randomized controlled trials. In this meta-analysis, we aimed to analyse the efficacy and safety profile of Mavacamten compared to placebo in patients of HCM. METHOD: We carried out a comprehensive search in PubMed, Cochrane, and clinicaltrials...
2024: PloS One
https://read.qxmd.com/read/38635085/clinical-and-ex-vivo-effect-of-lasers-on-prevention-of-early-enamel-caries-systematic-review-meta-analyses
#4
REVIEW
Nermin H Abd El-Aal, Ahmad Mostafa Hussein Mohamad Mostafa Hussein, Avijit Banerjee, Hamdi Hosney Hammama
To investigate the in vivo and in situ effect of different types of lasers in prevention of enamel demineralization in high caries risk cases (around orthodontic brackets, around restoration and in caries susceptible pits and fissures). PubMed was searched using the following keyword sequence; (Laser therapy OR laser irradiation OR laser application) AND (enamel caries prevention OR enamel demineralization OR enamel remineralization OR early enamel caries OR early-enamel caries OR enamel resistance OR enamel decalcification OR white spot lesions WSLs OR incipient lesion OR enamel decay OR enamel Dissolution OR enamel microhardness) AND (clinical trial OR Randomized clinical trial OR In situ study)...
April 18, 2024: Lasers in Medical Science
https://read.qxmd.com/read/38634983/safety-of-linagliptin-in-patients-with-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#5
REVIEW
Hadir Aljohani, Fares S Alrubaish, Waad M Alghamdi, Fawaz Al-Harbi
BACKGROUND: Linagliptin is an oral dipeptidyl peptidase DPP-4 inhibitor, which is indicated for the treatment of Type 2 diabetes mellitus (T2DM) as monotherapy or add-on to therapy with other hypoglycemic drugs. OBJECTIVES: We aimed to summarize the evidence from randomized controlled trials (RCTs) to assess the safety of linagliptin focusing on cardiovascular risks among subjects with type 2 diabetes mellitus. METHODS: We conducted a systematic search across the following databases: Medline, Embase, the Cochrane Central Register of Controlled Trials and ClinicalTrials...
April 18, 2024: Therapeutic Innovation & Regulatory Science
https://read.qxmd.com/read/38634551/quantified-metrics-of-gastric-emptying-delay-by-glp-1-agonists-a-systematic-review-and-meta-analysis-with-insights-for-periprocedural-management
#6
JOURNAL ARTICLE
Brent Hiramoto, Thomas R McCarty, Nayna A Lodhia, Andrew Jenkins, Ahmed Elnaiem, Mayssan Muftah, Ryan Flanagan, Walter W Chan
INTRODUCTION: Divergent recommendations for periprocedural management of GLP-1 receptor agonist (GLP-1 RA) medications rely on limited evidence. We performed a systematic review and meta-analysis to provide quantitative measures of gastric emptying relevant to mechanisms of weight loss and to periprocedural management of GLP-1 RA. We hypothesized that the magnitude of gastric emptying delay would be low and of limited clinical significance to procedural sedation risks. METHODS: A protocolized search identified studies on GLP-1 RA that quantified gastric emptying measures...
April 18, 2024: American Journal of Gastroenterology
https://read.qxmd.com/read/38634515/nonspecific-oral-medications-versus-anti-calcitonin-gene-related-peptide-monoclonal-antibodies-for-migraine-a%C3%A2-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#7
REVIEW
Jennifer Robblee, Sameh M Hakim, John M Reynolds, Teshamae S Monteith, Niushen Zhang, Meredith Barad
OBJECTIVE: To compare calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) versus nonspecific oral migraine preventives (NOEPs). BACKGROUND: Insurers mandate step therapy with NOEPs before approving CGRP mAbs. METHODS: Databases were searched for class I or II randomized controlled trials (RCTs) comparing CGRP mAbs or NOEPs versus placebo for migraine prevention in adults. The primary outcome measure was monthly migraine days (MMD) or moderate to severe headache days...
April 18, 2024: Headache
https://read.qxmd.com/read/38634506/acute-effects-of-testosterone-on-whole-body-protein-metabolism-in-hypogonadal-and-eugonadal-conditions-a-randomized-placebo-controlled-crossover-study
#8
JOURNAL ARTICLE
Marie Juul Ornstrup, Christian Høst, Nikolaj Rittig, Claus H Gravholt
Chronic testosterone (T) substitution and short-term T administration positively affect protein metabolism, however, data on acute effects in humans are sparse. This study aimed to investigate T's acute effects on whole-body protein metabolism in hypogonadal and eugonadal conditions. We designed a randomized, double-blind, placebo-controlled, crossover study, including twelve healthy young males. Whole-body protein metabolism was evaluated during 1) eugonadism, and after medically-induced hypogonadism, with application of a gel on each trial day containing either 2) placebo, 3) T 50 mg, or 4) T 150 mg; under basal (5h basal period) and insulin-stimulated conditions (3h clamp)...
April 18, 2024: Journal of Applied Physiology
https://read.qxmd.com/read/38633734/evaluation-of-the-effect-of-nigella-sativa-oil-on-the-outcome-of-missed-abortion-in-women-a-randomized-double-blind-clinical-trial
#9
JOURNAL ARTICLE
Belgheis Mohammadi, Leila Nazari Robati, Zeinab Tavakol, Mina Movahhed
BACKGROUND AND AIM: Due to the concern about the side effects of chemical drugs and their ineffectiveness, the use of natural compounds as alternatives or complementary therapies has received increasing attention. The purpose of this study was to investigate the effect of Nigella sativa oil on the outcome of missed abortion. METHODS: In this double-blind clinical trial, 70 nulliparous pregnant women referred to Hajar Hospital and Imam Ali clinics of Shahrekord and had missed abortion before the 12-week gestational age were selected and randomly divided into two interventions and control groups...
April 2024: Health Science Reports
https://read.qxmd.com/read/38633263/boosting-the-immunogenicity-of-the-coronavac-sars-cov-2-inactivated-vaccine-with-huoxiang-suling-shuanghua-decoction-a-randomized-double-blind-placebo-controlled-study
#10
JOURNAL ARTICLE
Ruying Tang, Linyuan Wang, Jianjun Zhang, Wenting Fei, Rui Zhang, Jinlian Liu, Meiyu Lv, Mengyao Wang, Ruilin Lv, Haipeng Nan, Ran Tao, Yawen Chen, Yan Chen, Yanxin Jiang, Hui Zhang
INTRODUCTION: In light of the public health burden of the COVID-19 pandemic, boosting the safety and immunogenicity of COVID-19 vaccines is of great concern. Numerous Traditional Chinese medicine (TCM) preparations have shown to beneficially modulate immunity. Based on pilot experiments in mice that showed that supplementation with Huoxiang Suling Shuanghua Decoction (HSSD) significantly enhances serum anti-RBD IgG titers after inoculation with recombinant SARS-CoV-2 S-RBD protein, we conducted this randomized, double-blind, placebo-controlled clinical trial aimed to evaluate the potential immunogenicity boosting effect of oral HSSD after a third homologous immunization with Sinovac's CoronaVac SARS-CoV-2 (CVS) inactivated vaccine...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38632977/efficacy-of-risankizumab-across-subgroups-in-patients-with-active-psoriatic-arthritis-a-post-hoc-integrated-analysis-of-the-phase-3-keepsake-1-and-keepsake-2-randomized-controlled-trials
#11
JOURNAL ARTICLE
Joseph F Merola, April Armstrong, Saakshi Khattri, So Yeon Paek, Byron Padilla, Cuiyong Yue, Huzefa Photowala, Blair Kaplan, Lars Erik Kristensen
In the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) phase 3 trials, risankizumab demonstrated greater efficacy compared with placebo in patients with active psoriatic arthritis (PsA). This post hoc integrated analysis evaluated achieving the following efficacy outcomes at weeks 24 and 52 by baseline demographics and clinical characteristics: ≥20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70), ≥90% improvement in Psoriasis Area and Severity Index, minimal disease activity status, Low Disease Activity status (Disease Activity in Psoriatic Arthritis), and minimal clinically important difference in pain...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38632457/a-randomized-double-blind-placebo-controlled-phase-iia-clinical-study-on-investigating-the-efficacy-and-safety-of-sph3127-tablet-in-patients-with-essential-hypertension
#12
JOURNAL ARTICLE
Fang Wang, Ling Liu, Hongyun Ruan, Xiaoping Chen, Yue Zhang, Zaixin Yu, Yuhui Li, Yang Guan, Jiguang Wang, Kai Huang, Shunjiang Yu, Yuanyuan Cao, Cungang Ding, Lin Chang, Yaohua Huang, Xiangjuan Chen, Qiang Lv, Changsheng Ma
Around 70% of patients diagnosed with hypertension exhibit increased levels of renin. SPH3127, an inventive renin inhibitor, has shown favorable tolerability and sustained pharmacodynamic inhibitory impact on plasma renin activity (PRA) during previous phase I trials. This phase II study was conducted to investigate the efficacy and safety of SPH3127 in patients with essential hypertension. This study was conducted in patients with mild to moderate essential hypertension, utilizing a randomized, double-blind, placebo-controlled design...
April 17, 2024: Hypertension Research: Official Journal of the Japanese Society of Hypertension
https://read.qxmd.com/read/38631987/individualized-homeopathic-medicines-in-preventing-the-progression-from-pre-diabetes-to-diabetes-a-double-blind-randomized-placebo-controlled-parallel-arm-trial
#13
JOURNAL ARTICLE
Aryabrata Banerjee, Subhasish Ganguly, Sangita Saha, Pulakendu Bhattacharyya, Satyajit Naskar, Debraj Mukherjee, Shuvadip Ghosh, Prosenjit Maji, Subhranil Saha, Abdur Rahaman Shaikh, Priyanka Ghosh, Chandrima Chatterjee, Munmun Koley, Shyamal Kumar Mukherjee
CONTEXT: Pre-diabetes is a significant public health problem worldwide. India has a very high rate of progression from pre-diabetes to diabetes, 75-78 per thousand persons per year. OBJECTIVE: To study the efficacy of individualized homeopathic medicinal products (HMPs) against placebos in preventing the progression from pre-diabetes to diabetes. DESIGN: Six-month, double-blind, randomized (1:1), two parallel arms, placebo-controlled trial...
April 4, 2024: Explore: the Journal of Science and Healing
https://read.qxmd.com/read/38631764/safety-and-efficacy-of-losmapimod-in-facioscapulohumeral-muscular-dystrophy-redux4-a-randomised-double-blind-placebo-controlled-phase-2b-trial
#14
JOURNAL ARTICLE
Rabi Tawil, Kathryn R Wagner, Johanna I Hamel, Doris G Leung, Jeffrey M Statland, Leo H Wang, Angela Genge, Sabrina Sacconi, Hanns Lochmüller, David Reyes-Leiva, Jordi Diaz-Manera, Jorge Alonso-Perez, Nuria Muelas, Juan J Vilchez, Alan Pestronk, Summer Gibson, Namita A Goyal, Lawrence J Hayward, Nicholas Johnson, Samantha LoRusso, Miriam Freimer, Perry B Shieh, S H Subramony, Baziel van Engelen, Joost Kools, Olof Dahlqvist Leinhard, Per Widholm, Christopher Morabito, Christopher M Moxham, Diego Cadavid, Michelle L Mellion, Adefowope Odueyungbo, William G Tracewell, Anthony Accorsi, Lucienne Ronco, Robert J Gould, Jennifer Shoskes, Luis Alejandro Rojas, John G Jiang
BACKGROUND: Facioscapulohumeral muscular dystrophy is a hereditary progressive myopathy caused by aberrant expression of the transcription factor DUX4 in skeletal muscle. No approved disease-modifying treatments are available for this disorder. We aimed to assess the safety and efficacy of losmapimod (a small molecule that inhibits p38α MAPK, a regulator of DUX4 expression, and p38β MAPK) for the treatment of facioscapulohumeral muscular dystrophy. METHODS: We did a randomised, double-blind, placebo-controlled phase 2b trial at 17 neurology centres in Canada, France, Spain, and the USA...
May 2024: Lancet Neurology
https://read.qxmd.com/read/38631185/multi-species-synbiotic-supplementation-increased-fecal-short-chain-fatty-acids-and-anti-inflammatory-cytokine-interleukin-10-in-adult-men-with-dyslipidemia-a-randomized-double-blind-clinical-trial
#15
JOURNAL ARTICLE
Shekoufeh Salamat, Alireza Jahan-Mihan, Lida Gharibvand, Mohammad Reza Tabandeh, Anahita Mansoori
BACKGROUND: Mounting evidence revealed that an imbalance of Gut Microbiota (GM) leads to metabolic disorders. Synbiotics through regulation of GM composition can be an effective intervention in the management of metabolic diseases. This study aimed to investigate the effects of multi-species synbiotic supplementation on serum interleukin10 (IL-10) and fecal Short Chain Fatty Acids (SCFAs) in patients with dyslipidemia. METHODS: In this double-blind, randomized, placebo-controlled clinical trial, fifty-six adult men with dyslipidemia were randomly allocated to intervention and control groups and received either synbiotic or placebo powder twice a day for 12 weeks...
April 16, 2024: Cytokine
https://read.qxmd.com/read/38631003/overall-survival-with-adjuvant-pembrolizumab-in-renal-cell-carcinoma
#16
JOURNAL ARTICLE
Toni K Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Naomi B Haas, Howard Gurney, Piotr Sawrycki, Mauricio Mahave, Marine Gross-Goupil, Tian Zhang, John M Burke, Gurjyot Doshi, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, Stephane Oudard, Delphine Topart, Hans Hammers, Hiroshi Kitamura, David F McDermott, Adriano Silva, Eric Winquist, Jerry Cornell, Aymen Elfiky, Joseph E Burgents, Rodolfo F Perini, Thomas Powles
BACKGROUND: Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results regarding overall survival from the third prespecified interim analysis of the trial would also favor pembrolizumab was uncertain. METHODS: In this phase 3, double-blind, placebo-controlled trial, we randomly assigned (in a 1:1 ratio) participants with clear-cell renal-cell carcinoma who had an increased risk of recurrence after surgery to receive pembrolizumab (at a dose of 200 mg) or placebo every 3 weeks for up to 17 cycles (approximately 1 year) or until recurrence, the occurrence of unacceptable toxic effects, or withdrawal of consent...
April 18, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38630489/extended-clopidogrel-monotherapy-vs-dapt-in-patients-with-acute-coronary-syndromes-at-high-ischemic-and-bleeding-risk-the-opt-birisk-randomized-clinical-trial
#17
JOURNAL ARTICLE
Yi Li, Jing Li, Bin Wang, Quanmin Jing, Yujie Zeng, Aijie Hou, Zhifang Wang, Aijun Liu, Jinliang Zhang, Yaojun Zhang, Ping Zhang, Daming Jiang, Bin Liu, Jiamao Fan, Jun Zhang, Li Li, Guohai Su, Ming Yang, Weihong Jiang, Peng Qu, Hesong Zeng, Lu Li, Miaohan Qiu, Leisheng Ru, Shaoliang Chen, Yujie Zhou, Shubin Qiao, Gregg W Stone, Dominick J Angiolillo, Yaling Han
IMPORTANCE: Purinergic receptor P2Y12 (P2Y12) inhibitor monotherapy after a certain period of dual antiplatelet therapy (DAPT) may be an attractive option of maintenance antiplatelet treatment for patients undergoing percutaneous coronary intervention (PCI) who are at both high bleeding and ischemic risk (birisk). OBJECTIVE: To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing DAPT with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in birisk patients with acute coronary syndromes (ACS)...
April 17, 2024: JAMA Cardiology
https://read.qxmd.com/read/38630462/placebo-control-and-blinding-in-randomized-trials-of-procedural-interventions-a-systematic-review-and-meta-regression
#18
JOURNAL ARTICLE
Christopher A Rajkumar, Katharine E Thomas, Michael Foley, Sashiananthan Ganesananthan, Holli Evans, Florentina Simader, Sharan Syam, Daniel Nour, Catherine Beattie, Caitlin Khan, Rohin K Reddy, Fiyyaz Ahmed-Jushuf, Darrel P Francis, Matthew Shun-Shin, Rasha K Al-Lamee
IMPORTANCE: Unlike medications, procedural interventions are rarely trialed against placebo prior to becoming accepted in clinical practice. When placebo-controlled trials are eventually conducted, procedural interventions may be less effective than previously believed. OBJECTIVE: To investigate the importance of including a placebo arm in trials of surgical and interventional procedures by comparing effect sizes from trials of the same procedure that do and do not include a placebo arm...
April 17, 2024: JAMA Surgery
https://read.qxmd.com/read/38630428/effect-of-theophylline-on-stent-related-symptoms-in-patients-undergoing-double-j-ureteral-stent-insertion-a-randomized-controlled-trial
#19
JOURNAL ARTICLE
Alireza Pakdel, Abdolreza Mohammadi, Hossein Chivaee, Amirreza Shamshirgaran, Hossein Amirzargar, Reza Mohammadi Farsani, Fardin Asgari, Alireza Khajavi, Seyed Mohammad Kazem Aghamir
PURPOSE: To investigate the effect of oral theophylline on stent-related syndrome (SRS) after Double-J insertion. BACKGROUND: Double-J stent is widely using in many urological procedures. Infection, hematuria, and discomfort are some of common complication after stenting. Theophylline is a dimethylated xanthine that inhibits phosphodiesterase and blocks adenosine receptors. To relaxing effect of theophylline on smooth muscles and its effects on the urinary system, it seems it could reduce complications after inserting Double-J stent especially ureteral stent syndrome...
April 17, 2024: International Urology and Nephrology
https://read.qxmd.com/read/38630015/a-randomized-double-blind-placebo-controlled-trial-to-evaluate-the-safety-and-efficacy-of-live-bifidobacterium-longum-cect-7347-es1-and-heat-treated-bifidobacterium-longum-cect-7347-ht-es1-in-participants-with-diarrhea-predominant-irritable-bowel-syndrome
#20
JOURNAL ARTICLE
S Srivastava, U Basak, M Naghibi, V Vijayakumar, R Parihar, J Patel, P S Jadon, A Pandit, R R Dargad, S Khanna, S Kumar, R Day
To determine the efficacy of the probiotic Bifidobacterium longum CECT 7347 (ES1) and postbiotic heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in improving symptom severity in adults with diarrhea-predominant irritable bowel syndrome (IBS-D), a randomised, double-blind, placebo-controlled trial with 200 participants split into three groups was carried out. Two capsules of either ES1, HT-ES1 or placebo were administered orally, once daily, for 84 days (12 weeks). The primary outcome was change in total IBS-Symptom Severity Scale (IBS-SSS) score from baseline, compared to placebo...
2024: Gut Microbes
keyword
keyword
39999
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.